2100.HEALTH
PHASE 1Life Biosciences ER-100 — first-ever partial epigenetic reprogramming in humans, FDA-cleared Jan 2026 PHASE 1Retro Biosciences RTR242 — first-in-human dose Adelaide Dec 2025, AI-designed Yamanaka variants CAPITALAltos Labs $3B preclinical, Sentinel Cell program 2026 PHASE 2Intervene Immune TRIIM-X enrolling — 2.5yr biological age reversal in original 9-man trial SIGNALBuck Institute 2025: TPE+IVIG cut biological age 2.61 years on multi-omic clocks REGFDA Category 2 on BPC-157 — most peptide compounding restricted 2024-2025 RXSELECT trial: semaglutide cut cardiovascular events 20% in non-diabetics FRONTIERStem Cell Institute Panama — 'Golden Cells' umbilical cord MSCs, no FDA jurisdiction
// THE LONGEVITY TERMINAL

The directory for every clinic delivering aging-reversal therapy. Where, what, how much, how good.

// confirmed. brief queued.
filter: clear

Named clinics. Where the protocols actually run. The further down the table, the further outside FDA jurisdiction — and the more recently the molecule reached the patient. Click any row for services, treatments offered, and pricing tiers.

Clinic Country Focus Offerings Tier

Off-label prescriptions, OTC supplements, and procedures running today. Evidence ranges from large RCT (GLP-1) to single-trial speculation (HBOT, exosomes). Read the rating before reading the headline.

Sym Asset Status Evidence Hallmark Price
●●●●● Strong human RCTs
●●●● Early human data
●●●●● Animal + observational
●●●●● Preclinical / mechanistic
●●●● Speculative

The frontier. Five categories, fourteen named programs, $3B+ in known capital. First human reprogramming results expected 2026-2027. Where today's "speculative" becomes tomorrow's standard of care.

Sym Program Phase Lead Sponsor First results

Measure first or you're flying blind. Epigenetic clocks compress 20-year mortality studies into a 6-month feedback loop — the most important development in this guide.

Test Best option Cost Frequency